MedPath

Validation for safety and efficacy of axillary reverse mapping using ICG in terms of prevention for lymphedema of upper limb in breast cancer

Phase 1
Conditions
breast cancer
Registration Number
JPRN-UMIN000031880
Lead Sponsor
agasaki University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

patients with sensitivity to ICG or other drugs pregnant patients

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
percentage of lymph edema in upper limb adverse events
Secondary Outcome Measures
NameTimeMethod
percentage of detection of lymph ducts detail of lymph ducts local recurrence rate of axillary lymph nodes
© Copyright 2025. All Rights Reserved by MedPath